Skip to content
Search

Latest Stories

Vakeel Saab trailer: Pawan Kalyan is back with a bang

Vakeel Saab trailer: Pawan Kalyan is back with a bang

By Murtuza Iqbal

Pawan Kalyan was last seen on the big screen in the 2018 release Agnyaathavaasi. Now, after a gap of three years, the fans of the actor will get to watch him on the big screen in this year’s release Vakeel Saab.


The film, which is a remake of PINK, is slated to release on 9th April 2021, today, the makers have unveiled the trailer of the film. Boney Kapoor, who is presenting the film, took to Twitter to share the trailer.

He tweeted, “Ultimately Justice will win when you've the right person on your side #VakeelSaabTrailer https://youtu.be/P1xKV0Dmetg @PawanKalyan #SriramVenu @shrutihaasan @SVC_official @MusicThaman @yoursanjali @AnanyaNagalla @bayviewprojoffl @adityamusic #VakeelSaabOnApril9th.”

The trailer of the film is damn good, but of course, it will remind you of PINK. However, there are a few scenes (the action scenes) that are new here. One thing that impresses us a lot in the trailer is the background score; it is amazing.

Pawan Kalyan is fantastic in the titular role, and we are sure the film will be a treat for his fans. Nivetha Thomas and Prakash Raj also leave a mark.

Vakeel Saab is directed by Sriram Venu and produced by Raju – Shirish. This is the second remake of PINK. Earlier, the movie was remade in Tamil with the title Nerkonda Paarvai and featured Ajith Kumar in the lead role. It was a blockbuster at the box office.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less